NLS Total Liab from 2010 to 2024
| NLSP Stock | USD 3.38 0.11 3.36% |
Total Liabilities | First Reported 2010-12-31 | Previous Quarter 10.7 M | Current Value 6.6 M | Quarterly Volatility 1.8 M |
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.8 K, Interest Expense of 137.9 K or Selling General Administrative of 6.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
NLS | Total Liab |
Latest NLS Pharmaceutics' Total Liab Growth Pattern
Below is the plot of the Total Liab of NLS Pharmaceutics AG over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. NLS Pharmaceutics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
NLS Total Liab Regression Statistics
| Arithmetic Mean | 8,972,388 | |
| Geometric Mean | 8,769,460 | |
| Coefficient Of Variation | 20.17 | |
| Mean Deviation | 1,492,925 | |
| Median | 10,005,622 | |
| Standard Deviation | 1,809,516 | |
| Sample Variance | 3.3T | |
| Range | 5.5M | |
| R-Value | (0.58) | |
| Mean Square Error | 2.3T | |
| R-Squared | 0.34 | |
| Significance | 0.02 | |
| Slope | (234,235) | |
| Total Sum of Squares | 45.8T |
NLS Total Liab History
About NLS Pharmaceutics Financial Statements
NLS Pharmaceutics shareholders use historical fundamental indicators, such as Total Liab, to determine how well the company is positioned to perform in the future. Although NLS Pharmaceutics investors may analyze each financial statement separately, they are all interrelated. The changes in NLS Pharmaceutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on NLS Pharmaceutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 10.7 M | 6.6 M |
Pair Trading with NLS Pharmaceutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.Moving together with NLS Stock
| 0.62 | A | Agilent Technologies Sell-off Trend | PairCorr |
| 0.85 | ME | 23Andme Holding Upward Rally | PairCorr |
| 0.82 | VALN | Valneva SE ADR | PairCorr |
Moving against NLS Stock
| 0.75 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.75 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.73 | VCYT | Veracyte | PairCorr |
| 0.71 | VERA | Vera Therapeutics | PairCorr |
| 0.53 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.
The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.